NASPANVAC
Nasal Pandemic Influenza Vaccine
| Coordinatore | ARCHIMEDES DEVELOPMENT LIMITED
Organization address
address: Albert Einstein Centre Nottingham Science and Technology Park contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 4˙971˙768 € |
| EC contributo | 3˙573˙648 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-FP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-05-01 - 2012-04-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ARCHIMEDES DEVELOPMENT LIMITED
Organization address
address: Albert Einstein Centre Nottingham Science and Technology Park contact info |
UK (Nottingham) | coordinator | 0.00 |
| 2 |
EVICOM LTD
Organization address
address: "Lyndhurst Road, Ascentia House" contact info |
UK (ASCOT) | participant | 0.00 |
| 3 |
HEALTH PROTECTION AGENCY HPA
Organization address
address: Central Office - 7th Floor, Holborn Gate - High Holborn 330 contact info |
UK (LONDON) | participant | 0.00 |
| 4 |
RETROSCREEN VIROLOGY LTD
Organization address
address: NEW ROAD QUEEN MARY BIOENTERPRISE INNOVATION CENTRE 42 contact info |
UK (LONDON) | participant | 0.00 |
| 5 |
THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
Organization address
address: College Green - contact info |
IE (DUBLIN) | participant | 0.00 |
| 6 |
UNIVERSITA' DEGLI STUDI DI SIENA
Organization address
address: VIA BANCHI DI SOTTO 55 contact info |
IT (SIENA) | participant | 0.00 |
| 7 |
UNIVERSITETET I BERGEN
Organization address
address: Museplassen 1 contact info |
NO (BERGEN) | participant | 0.00 |
| 8 |
UNIVERSITY OF LEICESTER
Organization address
address: University Road contact info |
UK (LEICESTER) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The project is being undertaken in response to the need to develop an effective, user friendly, heat stable vaccine to control the highly pathogenic form of avian influenza virus (H5 and H7 subtypes) which has the potential to cause another global influenza pandemic. The overall objective of this programme is to develop a nasal avian influenza vaccine using ChiSys® (chitosan), which is a chitosan-based technology of Archimedes Development Ltd.. Chitosan has already been tested with several nasally delivered antigens pre-clinically and clinically with excellent results. The most effective way of controlling a pandemic flu would be via the nasal route as this route is advantaged to generate both systemic and mucosal antibodies; the latter allowing virus control at its point of entry. In comparison the currently used injection route cannot achieve the mucosal response. Intranasal vaccination has further advantages: avoids the need for injection and safe disposal of syringes, eliminate the risk of HIV transmission through re-use or accidental contact with body fluids, have greater public compliance and well-suited to rapid mass global vaccination programmes. The scientific objectives of the project are: induce both systemic and mucosal immunity, evaluation of efficacy and toxicity in preclinical studies, evaluation of efficacy and safety profile in humans, provide a substantial level of cross-immunity against a drifted strains of H5 or H7, effective at low dose to meet the global demands from limited vaccine stockpiles, thermal stability so as to avoid refrigeration for storage and transportation and user friendly vaccine applicator. The consortium members have extensive experience in their specialist fields which would enable the success of this project. ChiSys® would be an excellent candidate for developing an intranasal pandemic influenza vaccine to provide a quantum leap in successfully combating pandemic influenza globally.'